Form 4: Pliant Therapeutics CHRO Sells Shares for Tax Obligations

Pliant Therapeutics' Chief Human Resource Officer, Lily Cheung, sold 7,534 shares of common stock at a weighted average price of $1.28 to cover tax liabilities from RSU vesting.

Summary

• Lily Cheung, Chief Human Resource Officer of Pliant Therapeutics, Inc. (PLRX), reported a sale of 7,534 shares of common stock.
• The transaction occurred on January 20, 2026, as part of a pre-arranged Rule 10b5-1 plan.
• The shares were sold at a weighted average price of $1.28 per share, with prices ranging from $1.245 to $1.33.
• The purpose of the sale was to satisfy withholding tax liability in connection with the vesting of previously granted restricted stock units.
• Following this transaction, Lily Cheung beneficially owns 44,847 shares of common stock.
• The reported beneficial ownership includes 1,956 shares of Common Stock acquired through an Employee Stock Purchase Plan program.

Sentiment

Score: 6

Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations from RSU vesting, which is a common occurrence for executives. The inclusion of shares from an Employee Stock Purchase Plan is a minor positive, indicating continued participation in company equity programs.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on recent insider information.
• The sale was for a non-discretionary purpose, specifically to cover tax obligations arising from RSU vesting, which is a routine event for executives.
• The reporting person acquired 1,956 shares through an Employee Stock Purchase Plan, indicating ongoing participation in company equity programs.

Negatives

• An insider, the Chief Human Resource Officer, reduced her direct ownership in the company by 7,534 shares.
• The sale price of $1.28 per share is relatively low, although it was a non-discretionary sale for tax purposes.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sale represents a nondiscretionary transaction by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1.
• The sale price represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units.

Industry Context

This Form 4 reports an individual insider transaction and does not provide broader industry context or trends. Insider sales for tax purposes are common across various industries for executives receiving equity compensation.

Stakeholder Impact

• Shareholders: The sale by an executive slightly reduces insider ownership, but as it's for tax purposes and pre-arranged, it typically has minimal impact on investor sentiment or company valuation.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale by an executive to cover tax liabilities from RSU vesting, executed under a Rule 10b5-1 plan. Such transactions are common and do not typically signal a change in the company's fundamental outlook or the executive's confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Pliant Therapeutics, PLRX, Insider Sale, Form 4, Stock Transaction, Lily Cheung, CHRO, Restricted Stock Units, Tax Withholding, Rule 10b5-1 Plan, Employee Stock Purchase Plan